Pesticidal mixtures having synergistically enhanced action, comprising as active compounds 1a) at least one isoxazoline compound I of formula C.I.240: or the tautomers, enantiomers, diastereomers or salts thereof, and 2a) at least one active compound II selected from group A consisting of A.2 the GABA-gated chloride channel antagonist ethiprole; A.3 the sodium channel modulator alpha-cypermethrin; A.4 nicotinic acetylcholine receptor agonists/antagonists selected from the class of neonicotinoids consisting of dinotefuran, imidacloprid, spinosad (allosteric agonist), thiacloprid and thiamethoxam; A.5 the chloride channel activator abamectin; A.7 the compound affecting the oxidative phosphorylation chlorfenapyr; A.12 the inhibitor of the lipid synthesis spirotetramat; A.13 group of various compounds consisting of flonicamid and flubendiamide; or 1b) at least one isoxazoline compound I of formula C.I.456: or the tautomers, enantiomers, diastereomers or salts thereof, and 2b) at least one active compound II selected from group A consisting of A.2 GABA-gated chloride channel antagonists selected from ethiprole and fipronil; A.4 nicotinic acteylcholine receptor agonists/antagonists selected from the class of neonicotinoids consisting of acetamiprid, dinotefuran, imidacloprid, spinosad (allosteric agonist) and thiacloprid; A.5 the chloride channel activator abamectin; A.7 the compound affecting the oxidative phosphorylation chlorfenapyr; A.8 the inhibitor of the chitin biosynthesis buprofezin; A.12 the inhibitor of the lipid synthesis spirotetramat; A. 13 pymetrozine; comprising the active compound I and the active compound II in a weight ratio of from 500:1 to 1:100. 1a) at least one isoxazoline compound I of formula C.I.240: or the tautomers, enantiomers, diastereomers or salts thereof, and 2a) at least one active compound II selected from group A consisting of A.2 the GABA-gated chloride channel antagonist ethiprole; A.3 the sodium channel modulator alpha-cypermethrin; A.4 nicotinic acetylcholine receptor agonists/antagonists selected from the class of neonicotinoids consisting of dinotefuran, imidacloprid, spinosad (allosteric agonist), thiacloprid and thiamethoxam; A.5 the chloride channel activator abamectin; A.7 the compound affecting the oxidative phosphorylation chlorfenapyr; A.12 the inhibitor of the lipid synthesis spirotetramat; A.13 group of various compounds consisting of flonicamid and flubendiamide; or A.2 the GABA-gated chloride channel antagonist ethiprole; A.3 the sodium channel modulator alpha-cypermethrin; A.4 nicotinic acetylcholine receptor agonists/antagonists selected from the class of neonicotinoids consisting of dinotefuran, imidacloprid, spinosad (allosteric agonist), thiacloprid and thiamethoxam; A.5 the chloride channel activator abamectin; A.7 the compound affecting the oxidative phosphorylation chlorfenapyr; A.12 the inhibitor of the lipid synthesis spirotetramat; A.13 group of various compounds consisting of flonicamid and flubendiamide; 1b) at least one isoxazoline compound I of formula C.I.456: or the tautomers, enantiomers, diastereomers or salts thereof, and 2b) at least one active compound II selected from group A consisting of A.2 GABA-gated chloride channel antagonists selected from ethiprole and fipronil; A.4 nicotinic acteylcholine receptor agonists/antagonists selected from the class of neonicotinoids consisting of acetamiprid, dinotefuran, imidacloprid, spinosad (allosteric agonist) and thiacloprid; A.5 the chloride channel activator abamectin; A.7 the compound affecting the oxidative phosphorylation chlorfenapyr; A.8 the inhibitor of the chitin biosynthesis buprofezin; A.12 the inhibitor of the lipid synthesis spirotetramat; A. 13 pymetrozine; comprising the active compound I and the active compound II in a weight ratio of from 500:1 to 1:100. A.2 GABA-gated chloride channel antagonists selected from ethiprole and fipronil; A.4 nicotinic acteylcholine receptor agonists/antagonists selected from the class of neonicotinoids consisting of acetamiprid, dinotefuran, imidacloprid, spinosad (allosteric agonist) and thiacloprid; A.5 the chloride channel activator abamectin; A.7 the compound affecting the oxidative phosphorylation chlorfenapyr; A.8 the inhibitor of the chitin biosynthesis buprofezin; A.12 the inhibitor of the lipid synthesis spirotetramat; A. 13 pymetrozine; comprising the active compound I and the active compound II in a weight ratio of from 500:1 to 1:100.